Risk formulas in calcium oxalate urolithiasis
- PMID: 9228725
- DOI: 10.1007/BF02201855
Risk formulas in calcium oxalate urolithiasis
Abstract
In order to reflect the risk of calcium stone formation, risk formulas have been described in the literature with the objective of being able to predict the further course of the stone disease. Some of these formulas are reviewed in this paper. Various results were obtained when different risk expressions were related to the severity of the stone disease. Although a reliable prediction of the future course of the disease most certainly cannot be made by analysis of the variables included in these expressions, several of the risk formulas differed significantly between patients with and without recurrent stone formation during a reasonable follow-up period. Some risk formulas might thus be helpful, at least to some extent, in selecting those patients in whom continuous stone formation can be anticipated and in whom active therapeutic measures should be beneficial and worthwhile. With an increased understanding of the mechanisms of calcium oxalate stone formation and our possibilities of measuring the relevant risk factors, it is likely that improved risk formulas with an increased predictive power can be developed. Until this becomes a reality, in most cases we have to combine important information on the history and clinical observations of the disease with a risk formula that offers a high degree of discrimination with respect to the risk of further stone formation.
Similar articles
-
Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein.Clin Chem Lab Med. 2004 Mar;42(3):283-93. doi: 10.1515/CCLM.2004.052. Clin Chem Lab Med. 2004. PMID: 15080561
-
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105. Arch Ital Urol Androl. 2015. PMID: 26150027 Review.
-
Inhibitors of calcium oxalate crystallization and urolithiasis.Urol Int. 1992;48(4):409-14. doi: 10.1159/000282365. Urol Int. 1992. PMID: 1413303
-
Artificial neural networks for assessing the risk of urinary calcium stone among men.Urol Res. 2006 Feb;34(1):17-25. doi: 10.1007/s00240-005-0006-4. Epub 2006 Jan 6. Urol Res. 2006. PMID: 16397774
-
Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease.BJU Int. 2001 Jul;88(2):158-68. doi: 10.1046/j.1464-410x.2001.02308.x. BJU Int. 2001. PMID: 11446874 Review. No abstract available.
Cited by
-
Evaluating the associations between urinary excretion of magnesium and that of other components in calcium stone-forming patients.Int Urol Nephrol. 2019 Feb;51(2):279-284. doi: 10.1007/s11255-018-2036-1. Epub 2018 Dec 4. Int Urol Nephrol. 2019. PMID: 30515733
-
Clinical risk index in urolithiasis.Urol Res. 2009 Oct;37(5):283-7. doi: 10.1007/s00240-009-0208-2. Epub 2009 Jul 16. Urol Res. 2009. PMID: 19609518
-
A new approach to the diagnosis of children's urolithiasis based on the Bonn Risk Index.Pediatr Nephrol. 2008 Jul;23(7):1123-8. doi: 10.1007/s00467-008-0786-1. Epub 2008 Mar 12. Pediatr Nephrol. 2008. PMID: 18335253
-
Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1.Urol Res. 2005 Nov;33(5):394-7. doi: 10.1007/s00240-005-0486-2. Epub 2005 Sep 8. Urol Res. 2005. PMID: 16151774
-
[Urinary calculi. Metabolism and diagnosis].Urologe A. 2006 Sep;45 Suppl 4:181-4. doi: 10.1007/s00120-006-1184-6. Urologe A. 2006. PMID: 16927082 Review. German. No abstract available.